Clinical Trial Update: ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO) [Phase 3]

View source ↗

Summary

Phase 3 trial of iloprost for septic shock with persistent microperfusion defects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Septic Shock

Drugs mentioned

• Iloprost (iloprost)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Septic Shock Hyperdynamic | Phase 3 | Status: COMPLETED